While services and diagnostics define much of today's demand, the oligonucleotide synthesis market is also being shaped by chemistry choices, manufacturing investment, and the growth of nucleic acid medicines. Polaris Market Research reports that the market was valued at USD 3.55 billion in 2025 and is projected to grow from USD 4.07 billion in 2026 to USD 12.49 billion by 2034, at a CAGR of 15.01% from 2026 to 2034. This article focuses on technology, capacity, and therapeutic drivers relevant to manufacturers, developers, and contract partners.

Chemistry and Technology Segments

By technology or chemistry, the market is segmented into phosphoramidite chemistry, solid-phase synthesis, liquid-phase synthesis, enzymatic synthesis, and other advanced synthesis technologies. The chemical or solid-phase synthesis segment accounted for 66.2% of market revenue in 2025, the largest technology segment. Its established use in oligonucleotide production and controlled nucleotide addition supports wide adoption across research, diagnostic, and therapeutic applications.

The enzymatic synthesis segment is projected to grow at a CAGR of 18.6% during the forecast period. Growing demand for longer and more complex DNA sequences supports its use in gene editing, cell therapy, and synthetic biology applications. The report describes enzymatic synthesis as being explored as an alternative to traditional chemical methods, and as gaining attention for longer sequences and more sustainable manufacturing.

Automation, AI, and Manufacturing Trends

Polaris notes that oligonucleotide production is becoming more automated and flexible. Automation helps laboratories handle larger numbers of sequences with less manual work, while high-throughput systems can support parallel synthesis and faster processing. Automating purification and quality control can also increase consistency and reduce production times.

AI-assisted sequence design is another development. According to the report, it can help researchers select and optimize sequences, and improved purification methods may further help the development of complex oligonucleotides. In July 2026, DNA Script signed a distribution agreement with Imperial Life Sciences to expand access to its SYNTAX on-demand DNA synthesis platform in India, which combines synthesis, purification, and normalization in an automated workflow.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/oligonucleotide-synthesis-market 

Therapeutic Demand and siRNA Opportunities

The use of oligonucleotides in medicines is expanding. The report states that in 2025 the FDA approved new oligonucleotide therapies, including antisense and RNAi drugs, which indicates increasing clinical use of RNA-based medicines and generates demand for oligonucleotide development and manufacturing. In February 2026, the FDA launched a framework for developing individualized therapies for ultra-rare diseases, which Polaris sees as a new opportunity for customized nucleic acid medicines.

siRNA therapies are creating opportunities in gene silencing. FDA-approved siRNA medicines are used across areas such as cardiovascular and rare diseases, supporting continued interest in RNA-based therapeutics. The report adds that further development may increase the need for specialized siRNA design, synthesis, purification, and testing services. The pharmaceutical and biotechnology end-user segment is projected to grow at a CAGR of 16.5%, supported by use in drug development, gene modulation, and targeted therapies.

CDMO Capacity and Manufacturing Investment

Investment in advanced drug manufacturing is rising. In 2026, Aragen Life Sciences announced plans to add 500 kiloliters of new CDMO capacity, with oligonucleotides among its focus areas, which Polaris says can support demand for specialized manufacturing services. In July 2025, AstraZeneca announced plans to invest USD 50 billion in the U.S. by 2030, including a new large-scale drug-substance facility in Virginia for small molecules, peptides, and oligonucleotides.

Agilent Technologies launched Agilent Advanced Therapeutics in 2026 to combine its CDMO capabilities, including oligonucleotide manufacturing, across North America. The report describes an innovation ecosystem of synthesis companies, pharmaceutical firms, biotechnology companies, research institutes, and CDMO providers, where partnerships and investments fuel capacity expansion.

Challenges and Opportunities

Oligonucleotide manufacturing requires careful control of synthesis, purification, and quality testing, and longer or modified sequences make production more difficult. Specialized equipment and strict quality checks can raise costs when production moves to commercial scale. The report also lists the erosion of synthesis costs and the absence of a unified set of guidelines for therapeutic oligonucleotides as potential restraints, alongside challenges in large-scale synthesis and precise delivery of oligonucleotide drugs. Emerging market scope in developing countries is expected to present opportunities.

Regional and Competitive Snapshot

North America held 40.9% of market revenue in 2025, and Asia Pacific is projected to grow at a CAGR of 17.5%. Europe is expected to maintain steady growth, with Germany, the UK, and France investing in biotechnology research, while Latin America and the Middle East and Africa are expected to see moderate and gradual growth respectively. Key players include Agilent Technologies, Ansa Biotechnologies, ATDBio Ltd., Azenta Life Sciences (GENEWIZ), Bio-Synthesis, Eurofins Genomics, GenScript Biotech Corporation, Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Merck KGaA, Nitto Denko Avecia, Thermo Fisher Scientific, TriLink BioTechnologies, and Twist Bioscience Corporation.

Conclusion

Chemistry, automation, capacity, and RNA-based therapies are shaping the next phase of the oligonucleotide synthesis market. With USD 3.55 billion in 2025 and a projected USD 12.49 billion by 2034 at a 15.01% CAGR, companies that invest in scalable, high-quality production are well positioned. The full Polaris Market Research report provides detailed coverage for further planning.

More Trending Latest Reports By Polaris Market Research:

Canned Motor Pumps Market

Glass Substrate Market

High-speed Data Converter Market

Neobanking Market

Platelet Rich Plasma (PRP) Market

Very Small Aperture Terminal (VSAT) Market

Digital Agriculture Market

Dental Regeneration Market

Aquaculture Market